Immunotherapy Archives

News and Trends 12 Sep 2016

Celyad’s unique CAR-T approach is ready for Efficacy Studies

The Belgian company has completed a successful Phase I trial for its NKR-2 T-cell therapy in patients with Leukemia and Myeloma, with no safety issues or dose-limiting toxicity reported. Celyad can now embark on efficacy studies. Celyad definitely has an original story. The company started back in 2007 as Cardio3Bioscience, targeting cardiovascular diseases with cell therapy, but […]

September 12, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 6 Sep 2016

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Rigontec is taking a totally new RNA-based approach to immuno-oncology via the RIG-I receptors. The company extended its Series A fundraising to a third round, and some of the top European VC’s doubled its cash pile to almost €30M. Since launching in early 2014, Munich-based Rigontec has broken with traditional immuno-oncology and pioneered a new RNA avenue […]

September 6, 2016 - 4 minutesmins - By Evelyn Warner

sylvain carlioz stimunity immunooncology2

News and Trends 5 Sep 2016

This Parisian Biotech Startup wants to clear a Major Hurdle in Immuno-oncology

Immuno-oncology is definitely the most promising breakthrough in cancer research right now. But the main issue is  that only 20-30% of patients respond to this therapy because of a weak immune system. I met Sylvain Carlioz, the co-founder of Stimunity, who wants to solve that problem. Carlioz was working at the tech transfer office of […]

September 5, 2016 - 4 minutesmins - By Philip Hemme

nsclc cancer vaccine immunotherapy opdivo combo

News and Trends 17 Aug 2016

Bavarian Nordic gets hold of Opdivo for new Combination Phase II trial

Just after a major clinical failure, BMS is now shipping Opdivo to Bavarian Nordic for a Phase II trial. Sponsored by Bavarian Nordic, the planned trial will evaluate the combination of a cancer vaccine and the anti-PD-L1 checkpoint inhibitor. Checkpoint blocking has generated a lot of excitement in cancer treatments as part of the immuno-oncology […]

August 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 16 Aug 2016

How did Cancer Cell Therapy become reality?

Using the body’s own tools to eradicate cancers has been a dream of Medicine for quite some time. How did the field of immuno-oncology evolve into today’s Biotech hype? The near-miraculous results of immuno-oncology cell therapies have dominated news about cancer breakthroughs. Indeed, CAR-T is a game-changer and are at the forefront of the ways Biotech […]

August 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

servier sorrento pd 1 biotech chemo car t cancer

News and Trends 13 Jul 2016

French Pharma licenses California PD-1 Cancer Antibody for €710M

San Diego’s Sorrento Therapeutics has bagged a quarter-billion euro deal with Servier. The French Pharma giant will develop Sorrento’s PD-1 targeting platform – a key checkpoint inhibitor in Immuno-Oncology. Sorrento’s proprietary G-MAB library platform was used to identify and generate STI-A1110, an antibody which targets PD-1, one of the key targets in the rapidly developing immuno-oncology therapy […]

July 13, 2016 - 2 minutesmins - By Dani Bancroft

cormorant interleukin 8 bms immuno oncology

News and Trends 7 Jul 2016

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

Bristol-Myers Squibb wants to strengthen its immuno-oncology even further. For this, it is acquiring Cormorant – a Biotech developing immunotherapies in a deal that could go up to €460M. Based at the Karolinska Institute Science Park in Stockholm (Sweden), Cormorant was a private Biotech focusing on cancer immunotherapies. Its main program was HuMax-IL8, which is currently in Phase […]

July 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

bristol myers squibb immunooncology cancer opdivo psioxus

News and Trends 1 Jul 2016

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients. Together they will evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Opdivo blockbuster (nivolumab), which […]

July 1, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 23 Jun 2016

Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins, thought to be the main cause of this major disease. Alzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients […]

June 23, 2016 - 2 minutesmins - By Denise Neves Gameiro

crispr cas9 clinical trial t cell therapy

News and Trends 22 Jun 2016

World’s first CRISPR Clinical trial has just been Approved!

CRISPR has received a regulatory green light in what could be the first clinical trial with the “scientific discovery of the century”. It’ll be used to improve cancer cell therapies. CRISPR has already revolutionized biotech, quickly overtaking the field of gene editing. It also has immense potential in the therapeutic field, so it’s not surprising there’s a lot […]

June 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 20 Jun 2016

Meet the Biotech successfully using Bacteria for Immuno-Oncology

Yes, the title may have surprised you, but it’s true. Vaximm is one of the few biotechs worldwide using bacteria to activate the immune system against cancer. I was really surprised about how elegant the technology is when I had a chat with the Executive Chairman Klaus Breiner at BioEquity in Copenhagen. Vaximm is based in Basel […]

June 20, 2016 - 4 minutesmins - By Philip Hemme

circassia grass allergy peptide spire trial

News and Trends 31 May 2016

UK Immunotherapy against Grass Allergies moves on to Phase III Trials

Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This common type of allergy can significantly impact the life quality of patients. Circassia is based in Oxford (UK) and was part of 2014’s record Biotech IPOs – raising a whopping €268M. It focuses on respiratory diseases, such as asthma and allergies. Its […]

May 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Celyad’s unique CAR-T approach is ready for Efficacy Studies

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

This Parisian Biotech Startup wants to clear a Major Hurdle in Immuno-oncology

Bavarian Nordic gets hold of Opdivo for new Combination Phase II trial

How did Cancer Cell Therapy become reality?

French Pharma licenses California PD-1 Cancer Antibody for €710M

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

World’s first CRISPR Clinical trial has just been Approved!

Meet the Biotech successfully using Bacteria for Immuno-Oncology

UK Immunotherapy against Grass Allergies moves on to Phase III Trials

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!